Industry Has 45 Days To Implement DEA’s Rescheduling Of Hydrocodone Combo Products
This article was originally published in The Pink Sheet Daily
DEA reschedules hydrocodone combination products from Schedule III to Schedule II with 45-day effective date; industry had requested more time to implement handling requirements.
You may also be interested in...
FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.
NCI networks had vast under accrual in the past year, but Sharpless says industry has been affected to a greater degree. He says the institute also has been better at accruing minority patients.
FDA’s 2019 survey of 2,000 providers finds 31% do not know what biosimilars are and 30% of primary care physicians do not know what an accelerated approval drug is. Another survey of low- or non-internet users finds a toll-free number is the best way for them to find information about a drug’s risks.